SUNNYVALE, Calif., Jan. 19 /PRNewswire-FirstCall/ -- Arrayit Corporation (OTC Bulletin Board: ARYC), a life sciences-focused
Personalized Medicine focuses on the use of a patient's clinical, genetic, genomic and environmental information to select a medication and determine optimal dosage, or to choose a therapy, or recommend preventative health measures. The goal of Personalized Medicine is to optimize the healthcare and medical outcomes for each individual.
PMWC's technology showcase will feature selected companies recognized for their breakthrough products and services. The "TOP 5" presenters will move to a semi-final stage to compete for the "PMWC 2010 Most Promising Company Award." The event is being hosted by Silicom Ventures, one of the largest angel and venture capitalist investment forums and funds in the United States, and will take place on January 19-20, 2010.
Arrayit founder and Executive Vice President Todd Martinsky will present the Company's growth strategy, which includes the development of new microarray-based pre-symptomatic tests for the diagnosis of Ovarian Cancer (OvaDx), Parkinson's Disease and Prostate Cancer. The Company will market and sell its diagnostic tests through its subsidiary, Arrayit Diagnostics, Inc.
About Arrayit Diagnostics, Inc.
Arrayit Diagnostics, Inc., a majority-owned subsidiary of Arrayit Corporation, is actively engaged in developing and commercializing a series of proprietary microarray-based diagnostic tests that provide for early detection of cancers, neurodegenerative diseases and other chronic and severe disease states.
About Arrayit Corporation
Arrayit Corporation leads and empowers the genetic, research, pharmaceutical and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 10,000 laboratories worldwide, including almost every major university, pharmaceutical and biotechnology company, major agricultural and chemical companies, government agencies, national research foundations and many private sector enterprises. Please visit www.arrayit.com for more information.
Safe Harbor Statement
Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009, Form 10-Q/A for the fiscal second quarter ended June 30, 2009 and Form 10-Q for the fiscal third quarter ended September 30, 2009.
FOR MORE INFORMATION, PLEASE CONTACT:
Elite Financial Communications Group
Dodi Handy, President and CEO (Twitter: @dodihandy)
For Media Inquiries: Kathy Addison, Director, Elite Media Group (Twitter: @kathyaddison)
407-585-1080 or via email at [email protected]
SOURCE Arrayit Corporation
Subscribe to our Free Newsletters!
Hyperacusis is a chronic hearing disorder characterized by an abnormal sensitivity to s ...
Proton beam therapy is a type of external radiation treatment or radiotherapy that uses protons ...
Statins are a group of drugs which help to lower the blood cholesterol levels.View All